The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

Keytruda + chemo improved OS in HER2-negative gastric or GEJ cancer regardless of PD-L1 expression

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Results from the pivotal phase III KEYNOTE-859 trial showed that Keytruda (pembrolizumab) plus chemotherapy significantly improved overall survival for patients with human epidermal growth factor receptor 2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma, regardless of PD-L1 expression. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account